The global immunology market is driven by the rising approvals of innovative drugs and biosimilars, prominent acquisitions and collaborations, continuous progress in clinical trials, and a rapid shift towards CAR-T cell therapy and oral treatments. This report encompasses blockbuster medications, noteworthy approvals from FDA and EMA, ongoing clinical trials with top 10 indications, biosimilars landscape, and forthcoming trends in treatment and diagnostic approaches.